A First-in-Human, Phase 1a, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Healthy Adult Subjects
Latest Information Update: 27 May 2024
At a glance
- Drugs STAR-0215 (Primary) ; STAR-0215 (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Astria Therapeutics
- 24 May 2024 According to an Astria Therapeutics media release, the company will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.
- 04 Mar 2024 According to an Astria Therapeutics media release, the final results from the Phase 1a trial were shared at the AAAAI Annual Meeting in Washington D.C.
- 26 Feb 2024 Complete results from the first three and interim results for the last two cohorts presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology